Colorectal Cancer: A Comprehensive Treatment Guide

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and women in the United States and the second leading cause of cancer death when men and women are combined. The American Cancer Society estimates approximately 153,000 new cases of colorectal cancer and 53,000 deaths annually in the U.S. However, both incidence and mortality rates have been declining for several decades in adults over 50, largely due to the widespread adoption of colonoscopy screening, which can detect and remove precancerous polyps before they become malignant.

A concerning trend, however, is the rising incidence in younger adults. Colorectal cancer rates in people under 50 have been increasing by about 1–2% per year since the mid-1990s, prompting the ACS to lower the recommended screening age from 50 to 45 in 2018.

What Is Colorectal Cancer?

Colorectal cancer begins in the colon (large intestine) or the rectum (the last several inches of the colon before the anus). Most colorectal cancers develop from adenomatous polyps—abnormal growths on the inner lining of the colon or rectum that can slowly transform into cancer over a period of 10–15 years. This slow progression from polyp to cancer creates a window of opportunity for screening to prevent cancer entirely by removing polyps before they become malignant.

The vast majority of colorectal cancers (approximately 95%) are adenocarcinomas, arising from the glandular cells that line the colon and rectum. Less common types include carcinoid tumors, gastrointestinal stromal tumors (GISTs), lymphomas, and squamous cell carcinomas.

Screening and Prevention

Colorectal cancer screening is one of the most powerful tools in cancer prevention because it can both detect cancer early and prevent cancer by identifying and removing precancerous polyps. The ACS and USPSTF recommend that adults at average risk begin regular screening at age 45.

Screening Methods

People at higher risk (family history of CRC, inflammatory bowel disease, Lynch syndrome, or familial adenomatous polyposis) may need earlier and more frequent screening. View our complete screening guide.

The Polyp-to-Cancer Sequence

Understanding the adenoma-carcinoma sequence is fundamental to colorectal cancer prevention. Most colorectal cancers develop through a stepwise process:

1. Normal mucosa — The healthy lining of the colon
2. Aberrant crypt foci — Microscopic clusters of abnormal cells
3. Adenomatous polyp (adenoma) — A benign growth that has the potential to become cancerous. Risk increases with polyp size (greater than 1 cm), villous histology, and high-grade dysplasia.
4. Carcinoma in situ — Cancer cells confined to the polyp
5. Invasive carcinoma — Cancer that has penetrated through the muscularis mucosae

This process typically takes 10–15 years, providing ample time for screening intervention. The two main molecular pathways involved are the chromosomal instability (CIN) pathway (involving APC, KRAS, and TP53 mutations) and the microsatellite instability (MSI) pathway (involving DNA mismatch repair deficiency, relevant to Lynch syndrome).

Risk Factors

• Age — Risk increases significantly after age 45–50, though younger-onset cases are rising.
• Personal or family history — Prior colorectal polyps or cancer, or a first-degree relative with CRC, doubles the risk.
• Hereditary syndromes — Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) accounts for about 3–5% of CRC. Familial adenomatous polyposis (FAP) causes hundreds to thousands of polyps and near-certain cancer without prophylactic surgery.
• Inflammatory bowel disease — Ulcerative colitis and Crohn's disease increase risk, particularly with long-standing, extensive disease.
• Lifestyle factors — Obesity, physical inactivity, red and processed meat consumption, heavy alcohol use, and smoking all increase risk.
• Type 2 diabetes — Associated with increased CRC risk independent of obesity.
• Race and ethnicity — African Americans have the highest incidence and mortality rates among racial and ethnic groups in the U.S.

Colorectal Cancer Staging

Survival rates from SEER data. Outcomes vary based on tumor location, molecular features, and treatment response.

Treatment Options

Surgery

Surgical resection is the primary curative treatment for stages I through III colorectal cancer. The type of surgery depends on the tumor location and stage:

• Polypectomy — Removal of cancerous polyps during colonoscopy. Sufficient for some stage 0 and early stage I cancers.
• Colectomy (partial or segmental) — Removal of the section of colon containing the cancer along with nearby lymph nodes and a margin of normal tissue. The remaining bowel is reconnected (anastomosis). Can often be performed laparoscopically or robotically.
• Total abdominal colectomy — Removal of the entire colon, sometimes necessary for patients with FAP or synchronous cancers.
• Low anterior resection (LAR) or abdominoperineal resection (APR) — For rectal cancer. LAR preserves the anus; APR requires a permanent colostomy when the tumor is very close to the anal sphincter.

For rectal cancer, total mesorectal excision (TME) is the standard surgical technique, which removes the rectum and its surrounding fatty tissue envelope to minimize local recurrence.

Chemotherapy

Chemotherapy plays a major role in colorectal cancer treatment, particularly for stage III disease and selected high-risk stage II patients. Learn more about chemotherapy.

Adjuvant Chemotherapy (After Surgery)

• FOLFOX — The standard adjuvant regimen for stage III colon cancer. Combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. Given every two weeks for 3–6 months. The landmark MOSAIC trial demonstrated that FOLFOX reduces the risk of recurrence by approximately 20% compared to 5-FU/leucovorin alone.
• CAPOX (XELOX) — Capecitabine (an oral 5-FU prodrug) plus oxaliplatin. An alternative to FOLFOX with comparable efficacy and the convenience of oral dosing.
• Capecitabine or 5-FU/leucovorin alone — Used for patients who cannot tolerate oxaliplatin or for selected stage II patients at higher risk of recurrence.

The IDEA collaboration demonstrated that three months of adjuvant FOLFOX or CAPOX may be sufficient for many stage III patients (particularly lower-risk T1–3, N1), reducing the neuropathy associated with six months of oxaliplatin.

Chemotherapy for Metastatic Disease

• FOLFIRI — 5-FU, leucovorin, and irinotecan. A standard first- or second-line regimen for metastatic CRC, often combined with a targeted agent.
• FOLFOX — Also used in the metastatic setting, often combined with bevacizumab.
• FOLFOXIRI — A triplet regimen adding irinotecan to FOLFOX; used for fit patients with bulky or aggressive disease, particularly when tumor shrinkage is needed to enable surgery on liver metastases.

Neoadjuvant Therapy for Rectal Cancer

Locally advanced rectal cancer (stage II–III) is typically treated with neoadjuvant therapy before surgery. The standard approach has evolved from concurrent chemoradiation (5-FU or capecitabine with radiation) to total neoadjuvant therapy (TNT), which delivers all chemotherapy and radiation before surgery. TNT has shown improved pathological complete response rates and may improve overall outcomes. In select patients with a clinical complete response after TNT, a watch-and-wait (organ preservation) strategy may avoid surgery entirely, though this requires close surveillance.

Targeted Therapy

Molecular profiling of colorectal tumors guides targeted therapy selection in metastatic disease:

• Bevacizumab (Avastin) — An anti-VEGF antibody that inhibits tumor blood vessel formation. Commonly combined with FOLFOX or FOLFIRI as first-line treatment.
• Cetuximab (Erbitux) and panitumumab (Vectibix) — Anti-EGFR antibodies used for RAS wild-type (no KRAS or NRAS mutations) tumors, particularly left-sided primary tumors where they show the greatest benefit.
• Ramucirumab (Cyramza) — An anti-VEGFR2 antibody used in second-line treatment.
• Encorafenib (Braftovi) + cetuximab — For BRAF V600E-mutant metastatic CRC, which carries a particularly poor prognosis. The BEACON trial showed this combination significantly improves survival over standard chemotherapy.

Immunotherapy

Immunotherapy has been transformative for the approximately 15% of colorectal cancers that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR):

• Pembrolizumab (Keytruda) — Approved as first-line monotherapy for MSI-H/dMMR metastatic CRC, based on the KEYNOTE-177 trial showing superior progression-free survival versus chemotherapy.
• Nivolumab (Opdivo) with or without ipilimumab (Yervoy) — Approved for MSI-H/dMMR metastatic CRC after prior chemotherapy.
• Dostarlimab (Jemperli) — A PD-1 inhibitor that showed remarkable results in a small study of dMMR rectal cancer patients, with all patients achieving a clinical complete response after immunotherapy alone, potentially avoiding surgery, radiation, and chemotherapy entirely.

Universal MSI/MMR testing is now recommended for all colorectal cancers at diagnosis, as results inform both treatment decisions and screening for Lynch syndrome in family members.

Liver Metastasis Surgery

The liver is the most common site of colorectal cancer metastasis. Unlike many other cancers, surgical resection of colorectal liver metastases can be curative in selected patients, with five-year survival rates of 40–60% after successful hepatectomy. Chemotherapy is typically given before and/or after liver surgery. Ablation techniques (radiofrequency ablation, microwave ablation) may be used for smaller or unresectable lesions.

Related Cancer Guides